Follow The Filings

CRNX Crinetics Pharmaceuticals In

Health Care, filed as CRINETICS PHARMACEUTICALS IN (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.6%
  • $336M
  • 1 add

In 2026 Q2 Farallon Capital Management added to Crinetics Pharmaceuticals In.

Who owns this now

Largest portfolio weights among holders, up to 1.6% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 1.6%

Who owns CRNX

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 1.6% Add +7.8% 8,989,098 $336M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Congress

2 members of Congress traded CRNX in the last three years: 4 buys and 2 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Sell $15K–$50K Jul 30 filed Sep 4
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Apr 17, 2025 filed May 6, 2025
  4. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Mar 19, 2025 filed Apr 10, 2025
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jan 29, 2025 filed Feb 11, 2025
  6. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Sep 25, 2024 filed Oct 3, 2024

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.